[go: up one dir, main page]

BR0212606A - Combinação - Google Patents

Combinação

Info

Publication number
BR0212606A
BR0212606A BR0212606-0A BR0212606A BR0212606A BR 0212606 A BR0212606 A BR 0212606A BR 0212606 A BR0212606 A BR 0212606A BR 0212606 A BR0212606 A BR 0212606A
Authority
BR
Brazil
Prior art keywords
combination
pde4
nsaids
ulcers
inflammation
Prior art date
Application number
BR0212606-0A
Other languages
English (en)
Inventor
Thomas Klein
Hans-Peter Kley
Armin Hatzelmann
Manfrid Eltze
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of BR0212606A publication Critical patent/BR0212606A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçãO". A presente invenção refere-se à administração combinada de inibidores,de PDE4 e NSAIDs para o tratamento de uma doença inflamatória e/ou um distúrbio associado com inflamação ao mesmo em que minimiza os efeitos colaterais gastrointestinais, tais como erosões gástricas e úlcera, que estão freq³entemente associados com o uso de NSAIDS.
BR0212606-0A 2001-09-19 2002-09-17 Combinação BR0212606A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19
PCT/EP2002/010424 WO2003024489A2 (en) 2001-09-19 2002-09-17 Combination of a nsaid and a pde-4 inhibitor

Publications (1)

Publication Number Publication Date
BR0212606A true BR0212606A (pt) 2004-08-17

Family

ID=8176065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212606-0A BR0212606A (pt) 2001-09-19 2002-09-17 Combinação

Country Status (25)

Country Link
US (2) US20040242597A1 (pt)
EP (1) EP1429807B1 (pt)
JP (1) JP4588998B2 (pt)
KR (1) KR100949528B1 (pt)
CN (1) CN100496607C (pt)
AT (1) ATE355080T1 (pt)
AU (1) AU2002337105B2 (pt)
BR (1) BR0212606A (pt)
CA (1) CA2459757C (pt)
CY (1) CY1108011T1 (pt)
DE (1) DE60218497T2 (pt)
DK (1) DK1429807T3 (pt)
EA (1) EA008108B1 (pt)
ES (1) ES2282469T3 (pt)
HK (1) HK1066730A1 (pt)
HU (1) HU229442B1 (pt)
IL (2) IL160271A0 (pt)
MX (1) MXPA04002562A (pt)
NO (1) NO331756B1 (pt)
NZ (1) NZ532278A (pt)
PL (1) PL210463B1 (pt)
PT (1) PT1429807E (pt)
SI (1) SI1429807T1 (pt)
WO (1) WO2003024489A2 (pt)
ZA (1) ZA200402654B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (en) * 2003-05-28 2004-12-23 Glaxo Group Limited Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
CA2534316A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1
CA2542277A1 (en) * 2003-10-21 2005-05-12 Pharmacia Corporation Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
JP2008533090A (ja) * 2005-03-14 2008-08-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 心血管疾患の防止方法
EP1898894A1 (en) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Mrp iv inhibitors for the treatment of respiratory diseases
PT2012763E (pt) * 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
WO2009094528A1 (en) 2008-01-25 2009-07-30 High Point Pharmaceuticals, Llc TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS
BRPI0908276B8 (pt) * 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
WO2010097332A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
WO2010097334A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
CA2900302C (en) 2013-02-19 2018-07-03 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CN106795165B (zh) 2014-08-06 2019-09-10 辉瑞公司 咪唑并哒嗪化合物
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
US20230017266A1 (en) * 2019-12-03 2023-01-19 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
CA3206106A1 (en) 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
EP4405048A1 (en) * 2021-09-22 2024-07-31 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
SK6252000A3 (en) 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
JP2003503360A (ja) 1999-06-24 2003-01-28 ファルマシア コーポレイション 炎症性疾患の処置のための併用療法
DE60043318D1 (de) * 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
BR0107964A (pt) * 2000-01-31 2002-10-29 Pfizer Prod Inc Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4
PL356447A1 (en) * 2000-02-08 2004-06-28 Smithkline Beecham Corporation Method and compositions for treating an inflammatory disease
IL156460A0 (en) * 2001-01-31 2004-01-04 Pfizer Prod Inc Ether derivatives useful as inhibitors of pde4 isozymes
BR0207278A (pt) * 2001-02-15 2004-02-10 Altana Pharma Ag Derivados de ftalazinona-piperidina como inibidores de pde4

Also Published As

Publication number Publication date
CN100496607C (zh) 2009-06-10
DK1429807T3 (da) 2007-06-18
JP2005504077A (ja) 2005-02-10
ES2282469T3 (es) 2007-10-16
EP1429807B1 (en) 2007-02-28
CA2459757A1 (en) 2003-03-27
NO20041596L (no) 2004-06-18
CN1625411A (zh) 2005-06-08
AU2002337105B2 (en) 2008-03-20
DE60218497D1 (de) 2007-04-12
NZ532278A (en) 2006-02-24
CA2459757C (en) 2011-08-30
JP4588998B2 (ja) 2010-12-01
EA200400410A1 (ru) 2004-12-30
WO2003024489A3 (en) 2003-09-18
MXPA04002562A (es) 2004-05-31
PT1429807E (pt) 2007-05-31
US20040242597A1 (en) 2004-12-02
US20080255209A1 (en) 2008-10-16
US8242146B2 (en) 2012-08-14
KR20040053129A (ko) 2004-06-23
DE60218497T2 (de) 2007-11-08
NO331756B1 (no) 2012-03-19
CY1108011T1 (el) 2013-09-04
ZA200402654B (en) 2005-04-26
PL369472A1 (en) 2005-04-18
ATE355080T1 (de) 2006-03-15
IL160271A (en) 2008-03-20
KR100949528B1 (ko) 2010-03-25
HK1066730A1 (en) 2005-04-01
HUP0401582A3 (en) 2008-04-28
SI1429807T1 (sl) 2007-08-31
PL210463B1 (pl) 2012-01-31
EA008108B1 (ru) 2007-04-27
EP1429807A2 (en) 2004-06-23
IL160271A0 (en) 2004-07-25
WO2003024489A2 (en) 2003-03-27
HU229442B1 (hu) 2013-12-30
HUP0401582A2 (hu) 2004-11-29

Similar Documents

Publication Publication Date Title
BR0212606A (pt) Combinação
BRPI0410503B8 (pt) composição tópica e uso da composição
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
BR9904394A (pt) Dispositivos bioquìmicos com revestimentos antimicrobianos
BR122013008865B8 (pt) adenovírus oncolítico de replicação competente
ATE504557T1 (de) Aspirin-ausgelöste lipidmediatoren
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
PT2336184E (pt) Administração de agentes para o tratamento da inflamação
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
BR9812133A (pt) Análogos de gaba para prevenir e tratar danos gastrintestinais
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
BRPI9701248B1 (pt) Compostos para a terapia de tumores e distúrbios inflamatórios, produto farmacêutico e formulação farmacêutica dos mesmos
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
BR9807655A (pt) Uso de inibidores de lipase gastrintestinal.
BR0110210A (pt) Compostos para o tratamento de fibromialgia e sìndrome de fadiga crÈnica
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
EA200870584A1 (ru) Пролекарства пенема
BRPI0606872A2 (pt) uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
ATE404208T1 (de) Uridin-therapie für patienten mit erhöhten purin- werten

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: ALTERADO DE:ALTANA PHARMA AG.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: NYCOMED ASSET MANAGEMENT GMBH (DE)

B25A Requested transfer of rights approved

Owner name: NYCOMED GERMANY HOLDING GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.